Manifesto on inhaled triple therapy in asthma: an Interasma (Global Asthma Association - GAA) document.
Matteo BoniniAngelica I TiotiuGuillermo Guidos FogelbachIlaria BaiardiniFilippo CosiniJaime Correia de SousaAndras BikovSylvia NovakovaMarina LaborIgor KaidashevDenislava NedevaKrzysztof KowalStefan MihaicutaMarilyn Urrutia PereiraDirceu SoléPlamela NovakovaHerberto Chong-NetoLaura VrzyIgnacio J AnsoteguiJonathan A BernsteinLouis-Philippe BouletGiorgio Walter CanonicaLawrence DubuskeCarlos NunesJuan Carlos IvancevichPierachille SantusNelson RosarioAlexander EmelyanovPaschalis SteiropoulosPublished in: The Journal of asthma : official journal of the Association for the Care of Asthma (2022)
Objective: The optimal use of drug combinations for the management of asthma is providing significant results. This has prompted Interasma (Global Asthma Association) to take a position on inhaled triple therapy in asthma. Methods: We performed an extensive literature research to clinical trials, meta-analyses, randomized controlled trials and systematic reviews. Results: Starting from an extensive literature review, Interasma executive committee discussed and approved this Manifesto, developed by Interasma scientific network (INES) members. Conclusions: The manifesto describes the evidence gathered to date and states, advocates, and proposes issues on inhaled corticosteroid (ICS) plus long-acting beta 2 agonist (LABA) and long-acting muscarinic antagonists (LAMA) with the aim of challenging assumptions, fostering commitment, and bringing about change.